{"id":391060,"date":"2016-09-16T00:00:00","date_gmt":"2016-09-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0005-2016-biopharma-migraine-acute-treatments-current-treatment-us-2016\/"},"modified":"2026-04-29T11:43:20","modified_gmt":"2026-04-29T11:43:20","slug":"cutrcg0005-2016-biopharma-migraine-acute-treatments-current-treatment-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0005-2016-biopharma-migraine-acute-treatments-current-treatment-us-2016\/","title":{"rendered":"Migraine-Acute Treatments | Current Treatment | US | 2016"},"content":{"rendered":"<p>The acute migraine market is dominated by the oral triptans, although genericization of these agents as well as approvals in recent years of multiple non-oral triptans and non-triptans have begun to shift market dynamics. Triptans with unique modes of administration (e.g., injectable or patch formulations) provide options for migraineurs wishing to avoid GI effects and\/or who may require a faster onset of therapeutic action;\u00a0ergotamine derivatives, NSAIDs, opioid analgesics, and other non-opioid analgesics offer alternative mechanisms of action to triptans. The Migraine | Current Treatment overview provides a synopsis of current treatment goals, key therapies (including acute and prophylactic agents), and medical practice in the United States and EU5 markets for migraine. The Acute Migraine | Current Treatment | US detailed, expanded analysis explores how U.S. neurologists and general practitioners\/primary care physicians are currently treating their migraine patients, with a particular focus on use of acute therapies, as well as insight into the factors driving such prescribing habits.<\/p>\n","protected":false},"template":"","class_list":["post-391060","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391060\/revisions"}],"predecessor-version":[{"id":394183,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391060\/revisions\/394183"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}